Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HXTC T-cell therapy in HIV-infected individuals on ART
NCT02208167Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2015
- Primary completion
- Jan 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of HXTC in human immunodeficiency virus infection (HIV), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Safety and Tolerability. Started Apr 2015; status: completed.
02
Drugs
HXTC
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02208167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02208167.